Loading resource…

BMJ
The study evaluates the impact of spironolactone on women with facial acne who have not responded to topical treatments or antibiotics. Participants were randomly assigned to receive either spironolactone or a placebo, with outcomes measured at various intervals. The primary outcome focused on the quality of life related to acne, while secondary outcomes included self-assessment of improvement and adverse reactions. The trial was conducted across multiple centers in England and Wales, with a total of 413 women participating.
No account needed